Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14643830 | 0.85 | PKM (0.36) | SNCAMEN1APOBEC3AKMT2AAPOBEC3G | |
| SCHEMBL14617870 | 0.85 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL14617868 | 0.84 | FBP1 (0.38) | SLC5A2HTT | |
| SCHEMBL16090887 | 0.82 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL16727628 | 0.82 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL14617877 | 0.82 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL16727625 | 0.82 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL10177116 | 0.82 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL14617871 | 0.81 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL18522415 | 0.80 | SLC5A2 (0.40) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SNCA 3378/4885MEN1 3504/4885APOBEC3A 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.